<DOC>
	<DOCNO>NCT01698476</DOCNO>
	<brief_summary>The aim study provide adjunctive therapy vitamin D phenylbutyrate together standard anti-tuberculosis treatment significantly improve clinical recovery among patient untreated , active pulmonary tuberculosis .</brief_summary>
	<brief_title>Immune Reconstitution Tuberculosis Disease</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>HIV negative patient , adult patient &gt; 18 year start antiTB therapy . Newly diagnose pulmonary TB confirm microscopy culture also sputumnegative clinical TB case ( define accord WHO 2006 criterion sputum smearnegative TB ie . clinical symptom TB , chest Xray finding response standard treatment ) . Patients already start treatment antiTB drug 5 day . HIVpositive patient . History antiTB treatment past 2 year . Local extrapulmonary TB absence lung manifestation . Hypercalcaemia ( serum calcium &gt; 3 mmol/L ) identify baseline . Pregnant breast feed woman . Any known liver kidney function abnormality , malignancy patient treat cardiac glycoside .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>pulmonary TB</keyword>
	<keyword>cholecalciferol</keyword>
	<keyword>sodium phenylbutyrate</keyword>
	<keyword>antimicrobial peptide</keyword>
	<keyword>immune response</keyword>
</DOC>